GMAB

Genmab ADR

57.06

Oct 30 • 3:59 PM ET +0.57 (1.01%)

57.07

Aftermarket • 7:30 PM ET +0.01 (0.02%)

Healthcare Biotechnology Denmark Large NASD

Peers: BNTX INCY REGN SMMT ONC EXEL ARGX HALO JAZZ ASND

| Held by: IBB FBT AVDE CANC FTQI LOEV APIE ONEQ AADR AVIV

Scroll to Statements

Index	-
Market Cap	34.10B
Enterprise Value	37.87B
Income	785.93M
Sales	4.13B
Book/sh	9.98
Cash/sh	2.52
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	3029
IPO	Jun 01, 2009

P/E	45.19
Forward P/E	32.53
PEG	1.47
P/S	8.26
P/B	5.72
P/C	22.69
P/FCF	39.19
EV/EBITDA	26.55
EV/Sales	9.17
Quick Ratio	2.44
Current Ratio	2.46
Debt/Eq	0.89
LT Debt/Eq	0.83
Option/Short	Yes / Yes

EPS (ttm)	1.26
EPS next Y	1.75
EPS next Q	0.35
EPS this Y	-23.27%
EPS next Y	48.76%
EPS next 5Y	22.19%
EPS past 3/5Y	9.68% 6.84%
Sales past 3/5Y	22.11% 19.27%
EPS Y/Y TTM	-36.69%
Sales Y/Y TTM	21.75%
EPS Q/Q	-11.45%
Sales Q/Q	23.03%
Earnings	Aug 06 AMC
EPS/Sales Surpr.	37.92% 3.46%

Insider Own	1.75%
Insider Trans	0.00%
Inst Own	18.59%
Inst Trans	0.29%
ROA	8.28%
ROE	13.96%
ROIC	7.20%
Gross Margin	93.03%
Oper. Margin	32.27%
Profit Margin	19.04%
SMA20	37.03%
SMA50	53.73%
SMA200	87.06%
Trades

Shs Outstand	597.02M
Shs Float	587.09M
Short Float	1.12%
Short Ratio	1.73
Short Interest	6.60M
52W High	59.97 -4.85%
52W Low	23.62 141.57%
Volatility	9.91% 5.72%
ATR (14)	2.45
RSI (14)	87.58
Beta	0.83
Rel Volume	2.27
Avg Volume	3.82M
Volume	8,646,380

Perf Week	30.30%
Perf Month	65.15%
Perf Quarter	98.95%
Perf Half Y	115.73%
Perf YTD	85.26%
Perf Year	99.02%
Perf 3Y	102.20%
Perf 5Y	27.82%
Perf 10Y	242.21%
Recom	1.64
Target Price	62.25
Prev Close	56.49
Price	57.06
Change %	1.01%

Consensus

Buy

Avg. Price Target

$62.25

Implied Upside

+9.1%

Analysts18incl. previous ratings

Rating Distribution15 Buy · 1 Hold · 2 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 27, 2026	Upgrade	JJP Morgan	Neutral → Overweight
Jul 22, 2026	Upgrade	TTD Cowen	Hold → Buy	$43	-24.6%
May 27, 2026	Initiated	TTruist	Buy	$40	-29.9%
Apr 22, 2026	Upgrade	GGoldman	Neutral → Buy
Mar 27, 2026	Initiated	WWolfe Research	Outperform	$32	-43.9%
Mar 02, 2026	Initiated	WWells Fargo	Overweight	$40	-29.9%
Feb 17, 2026	Resumed	MMorgan Stanley	Equal-Weight	$34	-40.4%
Feb 17, 2026	Resumed	JJefferies	Buy	$41.50	-27.3%
Sep 23, 2025	Upgrade	GGuggenheim	Neutral → Buy	$43	-24.6%
Apr 01, 2025	Downgrade	BBernstein	Mkt Perform → Underperform
Mar 11, 2025	Upgrade	WWilliam Blair	Mkt Perform → Outperform
Feb 13, 2025	Upgrade	LLeerink Partners	Market Perform → Outperform	$27	-52.7%
Oct 08, 2024	Initiated	RRedburn Atlantic	Buy
Sep 04, 2024	Resumed	MMorgan Stanley	Equal-Weight	$31	-45.7%
Aug 20, 2024	Downgrade	JJP Morgan	Overweight → Neutral
Jul 15, 2024	Upgrade	RRBC Capital Mkts	Sector Perform → Outperform
Feb 23, 2024	Upgrade	BBMO Capital Markets	Market Perform → Outperform	$46 → $48	-15.9%
Jan 22, 2024	Downgrade	CCitigroup	Neutral → Sell
Dec 06, 2023	Upgrade	UUBS	Neutral → Buy
Nov 10, 2023	Upgrade	DDeutsche Bank	Hold → Buy

Oct-29-26 12:24PM	Genmabs bispecific halves risk of death in first-line HNSCC (Clinical Trials Arena)
12:06PM	Genmab soars to record highs after cancer drug succeeds in key trial (BioPharma Dive)
Oct-28-26 11:07PM	Why Did ETSY, REPL, GMAB Stocks Surge To 52-Week Highs Today? (Stocktwits) +28.25%
01:24PM	GMAB Stock Hits All-Time High After Genmabs Cancer Drug Trial Meets Primary Goals Heres What Investors Need To Know (Stocktwits)
01:21PM	Genmab Stock Surges to Record High as Cancer Drug Slashes Risk of Death by 50% (Barrons.com)
10:24AM	Loading…
10:24AM	Genmab stock surges 16% on positive cancer trial results (Investing.com)
09:41AM	Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer (Business Wire)
Oct-27-26 07:11AM	J.P. Morgan upgrades Genmab on cancer drug growth potential (Investing.com)
Oct-26-26 01:37PM	European stocks rebound as corporate optimism lifts mood ahead of rate decisions (Reuters)
07:00AM	Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (Business Wire)
05:18AM	Genmab shares jump 13% on colorectal cancer drug trial results (Investing.com)
04:41AM	European shares eebound on easing crude, Moodys French reprieve (Investing.com)
Oct-25-26 07:00AM	Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer (Business Wire)
Oct-24-26 07:01AM	Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer (Business Wire)
07:00AM	Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer (Business Wire)
12:44PM	Loading…
Oct-23-26 12:44PM	Genmab stock surges 9% following positive phase 3 ovarian cancer trial results (Investing.com) +9.48%
11:56AM	Genmab Announces Rinatabart Sesutecan (Rina-S) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer (Business Wire)
Oct-14-26 04:07AM	Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda (PR Newswire)
Oct-06-26 12:46PM	European shares rise as retreating bond yields and oil prices boost risk appetite (Reuters)
11:42AM	Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial (BioPharma Dive)
03:52AM	Genmab jumps as its lymphoma drug combo with AbbVie cuts progression, death risk (Investing.com)
03:38AM	European stocks rise 1% as French debt calms and ECBs Lane tempers hawks (Investing.com)
Oct-05-26 03:29PM	Genmab stock surges 11% on positive cancer drug trial data (Investing.com) +10.73%
02:54PM	AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (PR Newswire)
02:50PM	Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (Business Wire)
04:03AM	Genmab shares jump as ovarian cancer drug shows durable responses in trial (Investing.com)
Oct-03-26 03:40PM	Genmab Announces Rinatabart Sesutecan (Rina-S) Phase 2 RAINFOL-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer (Business Wire)
Aug-07-26 12:43PM	Genmab Stock Rises 4.4% as Drug Royalties Lift Outlook (GuruFocus.com)
Aug-06-26 07:20PM	Genmab AS (GMAB) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
01:28PM	Genmab shares jump 8% after upbeat results prompt 2026 outlook raise (Investing.com)
09:18AM	Loading…
Aug-05-26 09:18AM	Earnings To Watch: Genmab AS (GMAB) Q2 2026 -- GF Value Sees 47% Upside (GuruFocus.com)
Jul-23-26 04:00PM	Genmab and AbbVie Provide Clarification on Phase 3 EPCORE DLBCL-1 Trial Evaluating Epcoritamab (DuoBody-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) (Business Wire)
Jul-22-26 09:44AM	CoreWeave upgraded, IBM initiated: Wall Street's top analyst calls (The Fly)
Jul-06-26 01:45PM	Genmab Announces TEPKINLY (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma (Business Wire)
Jun-29-26 04:15PM	Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival (Business Wire) +5.57%
Jun-18-26 10:34AM	VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026 (Exec Edge)
Jun-13-26 12:45PM	Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (Business Wire)
Jun-11-26 10:45AM	Genmab Presents EPCORE FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients (Business Wire)
May-21-26 05:00PM	Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress (Business Wire)
May-12-26 01:37PM	Junk-Rated Firms Rush to Reprice Risky Debt as Demand Surges (Bloomberg)
May-07-26 02:46PM	DARZALEX royalties drive Genmabs Q1 revenue higher amid expansion push (Investing.com)
May-06-26 09:17AM	What To Expect From Genmab AS (GMAB) Q1 2026 Earnings (GuruFocus.com)
Apr-22-26 06:14AM	Genmab gains as Goldman upgrades stock to Buy on increased pipeline confidence (Investing.com)
Apr-13-26 09:35AM	Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S) in Combination with Bevacizumab in Advanced Ovarian Cancer (Business Wire)
Mar-27-26 09:46AM	Wix downgraded, TripAdvisor upgraded: Wall Street's top analyst calls (The Fly)
Mar-02-26 09:53AM	Netflix upgraded, Pinterest downgraded: Wall Street's top analyst calls (The Fly)
07:56AM	Here Are Mondays Top Wall Street Analyst Research Calls: AppLovin, Blue Owl Capital, CrowdStrike, Dutch Bros., Jet Blue, Novo Nordisk, PayPal, Twilio, and More (24/7 Wall St.)
Feb-23-26 07:39AM	Novo Nordisk flags board members for re-election amid restructuring efforts (Pharmaceutical Technology)
Feb-20-26 12:39PM	These Are The 5 Best Stocks To Buy Now Or Watch (Investor's Business Daily)
04:10AM	Genmab (GMAB) Reports 19% Revenue Growth to $3.7B in 2025 Driven by Proprietary Medicine Sales (Insider Monkey)
Feb-17-26 06:01PM	Genmab AS (GMAB) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions (GuruFocus.com)
01:46PM	Genmab A/S Q4 Earnings Call Highlights (MarketBeat)
Feb-16-26 07:15AM	Genmab AS (GMAB) Q4 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Feb-13-26 08:58AM	Is the Options Market Predicting a Spike in Genmab Stock? (Zacks)
05:19AM	H.C. Wainwright Bullish on ?Genmab A/S (GMAB) on Robust Sales for DARZALEX (Insider Monkey)
Feb-10-26 08:32AM	Here's What Will Drive AbbVie's Top-line Growth in 2026 (Zacks)
06:41AM	Where is Genmab A/S (GMAB) Headed According to Wall Street? (Insider Monkey)
Feb-04-26 12:28PM	AbbVie Beats on Q4 Earnings, Stock Down Despite Upbeat '26 View (Zacks)
Jan-30-26 10:36AM	$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium (PR Newswire)
02:07AM	EPKINLY Trial Results Prompt Price Target Cut for Genmab (GMAB) (Insider Monkey)
Jan-22-26 02:16PM	Alkermes Stock Earns Technical Rating Upgrade (Investor's Business Daily)
12:21AM	Genmab (GMAB)'s Future Potential Underappreciated by Market (Insider Monkey)
Jan-20-26 01:36PM	Genmab Lymphoma Study Misses Key Target, Analyst Still Sees Upside (Benzinga)
05:00AM	Genmab A/S (GMAB) Shares Gain Analyst Support as Deutsche Bank Sees Oncology Upside (Insider Monkey)
Jan-16-26 01:31PM	Genmab Announces Topline Results for Epcoritamab (DuoBody CD3xCD20) from Phase 3 EPCORE DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) (Business Wire)
Jan-15-26 02:33PM	Genmab A/S (GMAB): A Bull Case Theory (Insider Monkey)
01:23PM	Oric Pharmaceuticals Stock Sees Healthy RS Rating Jump To 80 (Investor's Business Daily)
Jan-13-26 02:20PM	Moderna Stock Gets Healthy Relative Strength Rating Jump (Investor's Business Daily)
Jan-07-26 09:00AM	Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence (Business Wire)
Dec-31-25 08:43AM	Here's Why Genmab A/S (GMAB) Rose in Q3 (Insider Monkey)
Dec-30-25 09:03AM	Genmab shelves Phase III lung cancer candidate (Pharmaceutical Technology)
08:20AM	Genmab to discontinue further development of acasunlimab (TipRanks)
Dec-29-25 08:12AM	Genmab Portfolio Prioritization Update (Business Wire)
Dec-26-25 01:48PM	Moderna Stock Sees Healthy Relative Strength Rating (Investor's Business Daily)
11:07AM	This Cancer-Fighting Biotech Surges Into Buy Zone As Earnings Soar 131% (Investor's Business Daily)
Dec-19-25 07:44AM	Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 (PR Newswire)
Dec-16-25 02:09PM	Pacira BioSciences Stock Earns Technical Rating Upgrade (Investor's Business Daily)
Dec-15-25 02:59PM	Catalyst Pharmaceuticals Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
Dec-12-25 01:36AM	Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period (Business Wire)
Dec-11-25 05:38PM	Dow Jones, Russell 2000 Hit Highs; Broadcom Sees AI Chip Sales Doubling (Investor's Business Daily)
Dec-10-25 12:40PM	ASH 2025: AbbVie and Genmabs Epkinly sets new standard in second-line FL (Clinical Trials Arena)
Dec-08-25 04:30PM	Genmab Announces New Data from Phase 1b/2 EPCORE CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT) (Business Wire)
Dec-07-25 07:50AM	Genmab Presents Pivotal Phase 3 Data from EPCORE FL-1 Trial Demonstrating Clinical Benefit of EPKINLY (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma (Business Wire)
Dec-06-25 09:30AM	Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) (Business Wire)
08:00AM	AI Plays Lead Five Stocks To Watch Near Buy Points (Investor's Business Daily)
Dec-04-25 02:02PM	How Stock Of The Day Genmab Is Leveraging An $8 Billion Deal To Stoke Its Next Chapter (Investor's Business Daily)
Nov-21-25 02:37PM	Fighting Cancer With 'Smart Bombs.' What New Treatments Mean For Wall Street. (Investor's Business Daily)
Nov-18-25 02:19PM	Vera Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
11:30AM	Genmab Announces EPKINLY (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma (Business Wire)
Nov-17-25 01:17PM	Edgewise Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
Nov-12-25 01:33PM	Ocular Therapeutix Stock Earns 81 RS Rating (Investor's Business Daily)
Nov-11-25 01:04PM	Syndax Pharmaceuticals Stock Earns RS Rating Upgrade (Investor's Business Daily)
Nov-06-25 06:05PM	Genmab AS (GMAB) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... (GuruFocus.com)
Nov-05-25 07:20AM	Genmab AS (GMAB) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Nov-03-25 09:05AM	Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting (Business Wire)
Oct-31-25 02:06PM	AbbVie Q3 Earnings & Sales Beat, 2025 EPS Outlook Raised (Zacks)
Oct-28-25 12:24PM	H.C. Wainwright Maintains a Buy Rating on Genmab A/S (GMAB) (Insider Monkey)
Oct-14-25 11:40AM	GMAB or TECH: Which Is the Better Value Stock Right Now? (Zacks)
Oct-10-25 12:19PM	Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going. (Barrons.com)
Oct-06-25 09:50AM	GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal (Zacks)

Show Previous News

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Co-FounderDr. Jan G.J. van de Winkel Ph.D.

Executive VP & CFOMr. Anthony Pagano CPA

Executive VP & Chief Technical Operations OfficerMr. Rayne Waller

Executive VPMr. Gregory David Emil Mueller

Executive VP & Chief People OfficerMr. Christopher Cozic

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GMAB

Genmab ADR

Upgrade your Finviz experience